Redivia is a spin-off project at TU Dresden. We will accelerate and improve success rates in drug discovery using innovative software to tackle key hurdles faced by biopharma customers. Disruptive virtual screening technologies combined with real-world drug development expertise allow Redivia to provide unique insight into the process and identify the optimal solution for discovery scientists.

Redivia addresses needs in drug design, finding new applications for old drugs or failed candidates, identification of “off-targets” responsible for unwanted side-effects and extending the lifetime of approved drugs by identifying new therapeutic areas.

Disruptive Software Technologies

Technology by Redivia


Redivia’s success builds on disruptive software technologies bundled in the Redivia Discovery Engine, which efficiently identifies drug candidates based on the geometry of protein binding sites and their interactions with compounds. The two most important algorithms in the RDDiscovery Engine are RDAlign and RDInteract, offering novel means to explore the drug-target space at a ground-breaking level of precision.

The major challenge to bridge chemical and target space far beyond chemical similarity and homology is overcome with cutting-edge algorithms based on local alignments of target structures (binding site similarity) and analysis of non-covalent interactions (drug-target interaction profiles).

Over 30 Years of Experience

The Team

Partnerships, Questions, Inquiries

Contact Redivia

Biotechnology Center
of TU Dresden

Tatzberg 47
01307 Dresden

Joachim Haupt, PhD
Business Development

+49 351 463 40064

The data you provide will only be used to answer your request, not shared, evaluated in any other way or stored beyond the statutory requirements. Further information can be found in our privacy policy.

The project Redivia is funded under the EXIST program by the German Federal Ministry for Economic Affairs and Energy and the European Social Fund.